A5060000517- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urinary Bladder and Prostate Research
- Urologic and reproductive health conditions
- Hormonal and reproductive studies
- Pelvic floor disorders treatments
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Urological Disorders and Treatments
- Sexual function and dysfunction studies
- Advanced MRI Techniques and Applications
- MRI in cancer diagnosis
- Kidney Stones and Urolithiasis Treatments
- Urinary and Genital Oncology Studies
- Genital Health and Disease
- Renal and related cancers
- Extracellular vesicles in disease
- PARP inhibition in cancer therapy
- COVID-19 Clinical Research Studies
- Pediatric Urology and Nephrology Studies
- Health Systems, Economic Evaluations, Quality of Life
- Inflammatory Biomarkers in Disease Prognosis
- Molecular Biology Techniques and Applications
- Ureteral procedures and complications
Policlinico Umberto I
2008-2025
Sapienza University of Rome
2015-2024
University of Turin
2023
Weatherford College
2020
Gleason (United States)
2020
Association for Symbolic Logic
2016
META Group
2016
IRCCS Ospedale San Raffaele
2006
University of Urbino
2003-2004
This study aimed to prospectively analyze the role of magnetic resonance spectroscopy imaging (MRSI) and dynamic-contrast enhancement (DCEMR) in detection prostate tumor foci patients with persistently elevated prostate-specific antigen levels (in range >or=4 ng/mL <10 ng/mL) prior negative random trans-rectal ultrasound (TRUS)-guided biopsy.This was a prospective randomized single-center study. One hundred eighty eligible cases were included Patients group A submitted second biopsy, whereas...
You have accessJournal of Urology1 Apr 2008ROLE OF DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE (MR) IMAGING AND PROTON MR SPECTROSCOPIC IN THE DETECTION LOCAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER Alessandro Sciarra, Valeria Panebianco, Stefano Salciccia, Ana Maria, Autran Gomez, Gentilucci, and Vincenzo Gentile SciarraAlessandro Sciarra More articles by this author , PanebiancoValeria Panebianco SalcicciaStefano Salciccia MariaAna Maria GomezAutran Gomez...
Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Cancer (PCa), resulting in large numbers of unnecessary biopsies missed cancer diagnoses. Nanovesicles called exosomes are directly detectable patient plasma here we explore the potential use plasmatic expressing PSA (Exo-PSA) distinguishing healthy individuals, BPH, PCa. Exosomes were obtained from samples 80 PCa, donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA...
No AccessJournal of UrologyAdult Urology1 Apr 2009Early Recovery Urinary Continence After Radical Prostatectomy Using Early Pelvic Floor Electrical Stimulation and Biofeedback Associated Treatment Gianna Mariotti, Alessandro Sciarra, Gentilucci, Stefano Salciccia, Andrea Alfarone, Giovanni Di Pierro, Vincenzo Gentile MariottiGianna Mariotti , SciarraAlessandro Sciarra GentilucciAlessandro Gentilucci SalcicciaStefano Salciccia AlfaroneAndrea Alfarone PierroGiovanni Pierro GentileVincenzo View...
Abstract Purpose To evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance (mpMRI) in predicting prostate cancer (PCa) clinically significant PCa (csPCa) on biopsies among men scheduled for initial biopsy. Methods In this single-center prospective study, 52 biopsy, based elevated total PSA level (> 3 ng/ml) or abnormal digital rectal examination, were consecutively included. All subjects underwent SelectMDx, determination mpMRI. Results...
Study Type – Clinical (prospective trial) Level of Evidence 2b What's known on the subject? and What does study add? In clinical practice, we know that it is necessary to identify new biomarkers can better detect prostate cancer (PC), at same time as reducing number unnecessary biopsies. Recently, studies have suggested most relevant scenario in which antigen 3 (PCA3) score could be used comprises patients with a previous negative biopsy persistently elevated PSA levels. At time, although...